{
	"jcr:created": "Tue May 30 2023 14:42:39 GMT+0000",
	"jcr:createdBy": "L.ambrosini@adiacent.com",
	"jcr:primaryType": "cq:Page",
	"jcr:content": {
		"jcr:created": "Tue May 30 2023 14:42:39 GMT+0000",
		"cq:lastReplicatedBy": "d.mariotti@adiacent.com",
		"cq:lastReplicationAction": "Activate",
		"jcr:createdBy": "L.ambrosini@adiacent.com",
		"cq:lastReplicatedBy_publish": "d.mariotti@adiacent.com",
		"sling:resourceType": "menarinimaster/components/page",
		"jcr:uuid": "9ad3995c-667d-4f03-a71e-15599b67961d",
		"jcr:title": "Clinical Trials",
		"cq:isDelivered": true,
		"jcr:versionHistory": "b7b4f265-d04d-4209-8e2a-7c0f2592da28",
		"jcr:predecessors": [
			"d25614b3-9b05-4185-a014-6007e142f3f6"
		],
		"jcr:isCheckedOut": true,
		"jcr:mixinTypes": [
			"mix:versionable"
		],
		"cq:lastReplicationAction_publish": "Activate",
		"cq:lastModified": "Thu Jun 01 2023 08:29:15 GMT+0000",
		"cq:lastModifiedBy": "L.ambrosini@adiacent.com",
		"jcr:primaryType": "cq:PageContent",
		"cq:lastReplicated": "Wed May 31 2023 10:15:35 GMT+0000",
		"cq:lastReplicated_publish": "Wed May 31 2023 10:15:35 GMT+0000",
		"cq:template": "/conf/menarini-stemline/settings/wcm/templates/menarini---details-page",
		"jcr:baseVersion": "d25614b3-9b05-4185-a014-6007e142f3f6",
		"root": {
			"layout": "responsiveGrid",
			"sling:resourceType": "menarinimaster/components/container",
			"jcr:primaryType": "nt:unstructured",
			"container": {
				"layout": "responsiveGrid",
				"sling:resourceType": "menarinimaster/components/container",
				"jcr:primaryType": "nt:unstructured",
				"internalheader": {
					"disableLazyLoading": "false",
					"jcr:lastModifiedBy": "m.papini@adiacent.com",
					"textIsRich": "true",
					"sling:resourceType": "menarinimaster/components/internalheader",
					"titleFromPage": "false",
					"isDecorative": "true",
					"jcr:lastModified": "Wed Apr 19 2023 15:11:57 GMT+0000",
					"jcr:primaryType": "nt:unstructured",
					"imageFromPageImage": "false",
					"fileReference": "/content/dam/menarini-stemline/assets/slideshow/internal-header/header_clinical_trials.png"
				},
				"container_266438554": {
					"jcr:lastModifiedBy": "d.mariotti@adiacent.com",
					"jcr:lastModified": "Thu May 18 2023 13:03:30 GMT+0000",
					"sling:resourceType": "menarinimaster/components/container",
					"jcr:primaryType": "nt:unstructured",
					"container": {
						"cq:styleIds": [
							"1677232233407"
						],
						"jcr:lastModifiedBy": "d.mariotti@adiacent.com",
						"jcr:lastModified": "Thu May 18 2023 13:03:34 GMT+0000",
						"sling:resourceType": "menarinimaster/components/container",
						"jcr:primaryType": "nt:unstructured",
						"breadcrumb": {
							"sling:resourceType": "menarinimaster/components/breadcrumb",
							"jcr:primaryType": "nt:unstructured"
						}
					}
				},
				"container": {
					"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
					"sling:resourceType": "menarinimaster/components/container",
					"layout": "responsiveGrid",
					"jcr:lastModified": "Wed Apr 19 2023 08:59:13 GMT+0000",
					"jcr:primaryType": "nt:unstructured",
					"internalmenu": {
						"structureStart": 0,
						"navigationRoot": "/content/menarini-stemline/en/en/science",
						"sling:resourceType": "menarinimaster/components/internalmenu",
						"jcr:primaryType": "nt:unstructured",
						"cq:responsive": {
							"jcr:primaryType": "nt:unstructured",
							"default": {
								"offset": "0",
								"width": "3",
								"jcr:primaryType": "nt:unstructured"
							},
							"tablet": {
								"offset": "0",
								"width": "4",
								"jcr:primaryType": "nt:unstructured"
							},
							"phone": {
								"offset": "0",
								"width": "12",
								"jcr:primaryType": "nt:unstructured"
							}
						}
					},
					"container": {
						"layout": "responsiveGrid",
						"cq:styleIds": [
							"1684771252337"
						],
						"sling:resourceType": "menarinimaster/components/container",
						"jcr:primaryType": "nt:unstructured",
						"title": {
							"cq:styleIds": [
								"1653552493699"
							],
							"jcr:lastModifiedBy": "m.papini@adiacent.com",
							"linkTarget": "_self",
							"sling:resourceType": "menarinimaster/components/title",
							"jcr:title": "OUR CLINICAL TRIALS",
							"type": "h2",
							"jcr:lastModified": "Mon Mar 06 2023 14:14:01 GMT+0000",
							"jcr:primaryType": "nt:unstructured",
							"cq:responsive": {
								"jcr:primaryType": "nt:unstructured"
							}
						},
						"cq:responsive": {
							"jcr:primaryType": "nt:unstructured",
							"default": {
								"offset": "0",
								"width": "8",
								"jcr:primaryType": "nt:unstructured"
							},
							"tablet": {
								"offset": "0",
								"width": "8",
								"jcr:primaryType": "nt:unstructured"
							},
							"phone": {
								"offset": "1",
								"width": "10",
								"jcr:primaryType": "nt:unstructured"
							}
						},
						"spacer": {
							"jcr:created": "Thu Jun 01 2023 08:29:07 GMT+0000",
							"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
							"jcr:createdBy": "L.ambrosini@adiacent.com",
							"sling:resourceType": "menarinimaster/components/spacer",
							"jcr:lastModified": "Thu Jun 01 2023 08:29:15 GMT+0000",
							"spacer": "40",
							"jcr:primaryType": "nt:unstructured"
						},
						"text": {
							"jcr:lastModifiedBy": "m.papini@adiacent.com",
							"textIsRich": "true",
							"sling:resourceType": "menarinimaster/components/text",
							"jcr:lastModified": "Mon Mar 06 2023 14:14:23 GMT+0000",
							"jcr:primaryType": "nt:unstructured",
							"text": "<p>Inspired by the goal to improve outcomes for patients with unmet medical needs, Stemline is a biopharmaceutical company driven to discover and develop innovative therapeutics for the treatment of cancer.</p>\r\n"
						}
					},
					"spacer": {
						"jcr:lastModifiedBy": "m.papini@adiacent.com",
						"sling:resourceType": "menarinimaster/components/spacer",
						"jcr:lastModified": "Tue Mar 28 2023 14:17:47 GMT+0000",
						"spacer": "50",
						"jcr:primaryType": "nt:unstructured"
					}
				},
				"container_1242765028": {
					"jcr:lastModifiedBy": "d.mariotti@adiacent.com",
					"jcr:lastModified": "Thu May 18 2023 13:04:51 GMT+0000",
					"sling:resourceType": "menarinimaster/components/container",
					"jcr:primaryType": "nt:unstructured",
					"container_1321963744": {
						"cq:styleIds": [
							"1677232233407"
						],
						"jcr:lastModifiedBy": "m.papini@adiacent.com",
						"jcr:lastModified": "Mon Mar 27 2023 10:25:45 GMT+0000",
						"sling:resourceType": "menarinimaster/components/container",
						"jcr:primaryType": "nt:unstructured",
						"pipeline_container": {
							"componentType": "componentClinicalTrials",
							"jcr:lastModifiedBy": "m.papini@adiacent.com",
							"jcr:lastModified": "Mon Mar 27 2023 14:57:54 GMT+0000",
							"sling:resourceType": "menarinimaster/components/pipeline-container",
							"jcr:primaryType": "nt:unstructured",
							"pipeline_item": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/elacestrant",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT03778931?term=Stemline&draw=2",
								"indicationValue": "Metastatic Breast Cancer - Monotherapy",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:29:29 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/elacestrant",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT05386108?term=Stemline&draw=2&rank=2",
								"indicationValue": "Metastatic Breast Cancer/Glioblastoma - Combination",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:34:39 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/elacestrant",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT05563220?term=Stemline&draw=2&rank=1",
								"indicationValue": "Metastatic Breast Cancer - Combination",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:34:31 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c_1187921545": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/elacestrant",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT05596409?term=Stemline&draw=2",
								"indicationValue": "Metastatic Breast Cancer - Combination",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:38:15 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c_870805836": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/men1703",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT03008187?term=NCT03008187&draw=2&rank=1",
								"indicationValue": "Acute Myeloid Leukemia (AML), Relapsed/Refractory",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:45:38 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c_1276338677": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/men1611",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT04495621?term=NCT04495621&draw=2&rank=1",
								"indicationValue": "Metastatic Colorectal Cancer",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:46:38 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c_1165662889": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/men1611",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://www.clinicaltrials.gov/ct2/show/NCT03767335?term=NCT03767335&draw=2&rank=1",
								"indicationValue": "Advanced or Metastatic Breast Cancer",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:47:20 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							},
							"pipeline_item_copy_c_276000136": {
								"compoundValue": "/content/dam/menarini-stemline/area-content-fragments/compound-dropdown-options/sl-901",
								"statusType": "open",
								"textIsRich": "true",
								"sling:resourceType": "menarinimaster/components/pipeline-item",
								"readMore": "<p>Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER&#43;)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER&#43;/ HER2- advanced or metastatic breast cancer.</p>\r\n",
								"clinicalTrials": "https://clinicaltrials.gov/ct2/show/NCT05382936?term=Stemline&draw=2&rank=3",
								"indicationValue": "Advanced Solid Tumors",
								"jcr:lastModifiedBy": "L.ambrosini@adiacent.com",
								"target": "_blank",
								"enableStage3": "false",
								"enableStage4": "false",
								"enableStage5": "false",
								"enableStage6": "false",
								"enableStage7": "false",
								"labeClinicalTrials": "View details",
								"jcr:lastModified": "Tue Apr 18 2023 10:48:21 GMT+0000",
								"jcr:primaryType": "nt:unstructured",
								"enableStage1": "false",
								"enableStage2": "false"
							}
						}
					}
				},
				"container_87346761": {
					"cq:styleIds": [
						"1655202404538"
					],
					"jcr:lastModifiedBy": "m.papini@adiacent.com",
					"sling:resourceType": "menarinimaster/components/container",
					"jcr:lastModified": "Mon Mar 06 2023 14:16:12 GMT+0000",
					"jcr:primaryType": "nt:unstructured",
					"container": {
						"cq:styleIds": [
							"1677232233407"
						],
						"jcr:lastModifiedBy": "m.papini@adiacent.com",
						"sling:resourceType": "menarinimaster/components/container",
						"layout": "responsiveGrid",
						"jcr:lastModified": "Mon Mar 06 2023 14:16:27 GMT+0000",
						"jcr:primaryType": "nt:unstructured",
						"banner": {
							"disableLazyLoading": "false",
							"linkTarget": "_blank",
							"textIsRich": "true",
							"sling:resourceType": "menarinimaster/components/banner",
							"jcr:title": "MENARINI’S CLINICAL TRIALS",
							"titleFromPage": "false",
							"isDecorative": "true",
							"linkURL": "https://www.menarini.com/en-us/innovation-research/clinical-trials/clinical-trials-database",
							"imageFromPageImage": "false",
							"cq:styleIds": [
								"1655107229265"
							],
							"jcr:lastModifiedBy": "m.papini@adiacent.com",
							"jcr:description": "<p>Like Stemline, Menarini Group believes clinical trials are instrumental to translating the promising results of scientific research into high-quality medicines capable of improving patients’ lives.</p>\r\n",
							"jcr:lastModified": "Fri May 05 2023 14:03:51 GMT+0000",
							"jcr:primaryType": "nt:unstructured",
							"fileReference": "/content/dam/menarini-stemline/assets/menu/megabox_men_clinical-trial.jpg",
							"descriptionFromPage": "false",
							"actions": {
								"jcr:primaryType": "nt:unstructured"
							}
						},
						"spacer_copy": {
							"jcr:lastModifiedBy": "m.papini@adiacent.com",
							"jcr:lastModified": "Tue Mar 28 2023 14:17:47 GMT+0000",
							"sling:resourceType": "menarinimaster/components/spacer",
							"spacer": "50",
							"jcr:primaryType": "nt:unstructured"
						}
					}
				}
			}
		}
	}
}